Drug Monograph

Drug/Drug Class:	**Liletta™ (levonorgestrel) intrauterine device / Pregnancy Prevention**
Prepared for:	MO HealthNet
Prepared by:	Xerox Heritage, LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Liletta™ is a levonorgestrel-releasing intrauterine system consisting of a T-shaped polyethylene frame with a drug reservoir containing 52 mg levonorgestrel, packaged within a sterile inserter.
Manufacturer:	Actavis Pharma, Inc., Parsippany, NJ 07054
Indications:	Liletta™ is indicated for prevention of pregnancy for up to 3 years. The system should be replaced after 3 years if continued use is desired.
Costs:	$631.25 per Liletta™ system. Maximum Allowable Cost
Summary of Findings:	The Division recommends adding this drug to the current non- oral contraceptive fiscal edit.
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☒ Fiscal Edit ☐ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Non-Preferred Agent ☒ Appropriate Indications ☐ No PA Required

Prepared By: Luke Boehmer Pharm.D.
Date: August 3, 2015